# DESCRIPTION

## FIELD OF THE INVENTION

- introduce fluorinated 4-azasteroid derivatives

## BACKGROUND OF THE INVENTION

- define androgen receptor
- describe androgen ligand binding
- explain gene transcription
- discuss androgen therapy
- motivate tissue-selective AR agonists
- describe role of androgens in bone formation
- discuss osteoporosis treatment
- describe androgen deficiency in men
- discuss ADT for prostate cancer
- motivate tissue-selective AR antagonists
- discuss polycystic ovarian syndrome
- describe osteoporosis statistics
- discuss bone resorption inhibitors
- motivate osteoanabolic agents
- discuss selective androgen receptor modulators
- describe hematopoietic disorders
- discuss obesity treatment
- summarize prior art

## SUMMARY OF THE INVENTION

- define compounds of structural formula I
- describe properties of compounds
- outline pharmaceutical compositions and methods of treatment
- list specific conditions for treatment

## DETAILED DESCRIPTION OF THE INVENTION

- define structural formula I
- specify R1, R2, and R3 substituents
- describe embodiments of compounds
- provide specific examples of embodiments
- define alkyl and aryl groups
- describe substituents for alkyl and aryl groups
- illustrate examples of compounds of the present invention
- list specific compounds of the present invention
- describe another embodiment of the invention
- list specific compounds of the present invention
- describe yet another variant of the compounds of the present invention
- list specific compounds of the present invention
- describe one embodiment of the invention
- list specific compounds of the present invention
- discuss stereochemistry and tautomers of the compounds
- define terms
- define aryl
- define alkyl
- define halogen
- define oxy, thio, oxo, carbonyl
- define substituted
- describe nomenclature rules
- introduce SARMs
- describe activation of AR in bone and muscle
- describe antagonism of AR in prostate
- describe treatment of conditions
- describe treatment of arthritic conditions
- describe treatment of conditions in male individuals
- describe treatment of conditions in female individuals
- describe use as adjuncts to traditional androgen depletion therapy
- describe pharmacological properties
- describe pharmaceutical compositions
- define administration of a compound
- define modulating a function mediated by the androgen receptor
- describe administration of a compound of structural formula I
- determine effective amount of a compound
- describe daily dosage of a compound of structural formula I
- describe formulation of a compound of structural formula I
- exemplify pharmaceutical composition
- describe process for making a pharmaceutical composition
- describe formulations for oral administration
- describe formulations for vaginal or rectal administration
- describe topical preparations
- describe liposome delivery systems
- describe monoclonal antibodies as carriers
- describe soluble polymers as targetable drug carriers
- describe biodegradable polymers for controlled release
- describe formulations suitable for parenteral administration
- describe combination therapy with other therapeutically active compounds
- describe treatment of osteoporosis with combination therapy
- describe bone antiresorptive agents
- introduce αvβ3 integrin receptor antagonists
- summarize prior art of αvβ3 integrin receptor antagonists
- describe cathepsin K and its relation to bone resorption
- introduce HMG-CoA reductase inhibitors (statins) for bone resorption treatment
- describe osteoclast vacuolar ATPase inhibitors (proton pump inhibitors)
- introduce VEGF antagonists for bone resorption treatment
- describe activators of peroxisome proliferator-activated receptor-γ (PPARγ)
- introduce calcitonin for bone resorption treatment
- describe protein kinase inhibitors, including p38 inhibitors
- introduce osteoanabolic agents, including parathyroid hormone (PTH)
- describe calcium receptor antagonists for inducing PTH secretion
- introduce growth hormone secretagogues and growth hormone releasing hormone
- describe insulin-like growth factor (IGF) and bone morphogenetic protein (BMP)
- introduce inhibitors of BMP antagonism
- describe tissue-selective androgen receptor modulators
- combine with osteoprotegerin for bone loss treatment
- combine with prostaglandin derivatives for bone metabolism
- combine with fibroblast growth factors for bone growth
- combine with other agents for bone health
- combine with vitamin D and derivatives for bone health
- combine with vitamin K and derivatives for bone health
- combine with soy isoflavones and fluoride salts for bone health
- describe daily dosage ranges for combined therapy
- combine with lipid-altering compounds for atherosclerosis treatment
- describe method for effecting bone turnover marker in a mammal

### ABBREVIATIONS USED IN THE DESCRIPTION OF THE PREPARATION OF THE COMPOUNDS OF THE PRESENT INVENTION

- define abbreviations

### Preparation of the Compounds of the Invention

- introduce preparation procedures
- describe Scheme 1
- describe Scheme 2
- describe Scheme 3
- describe Scheme 4
- provide Example 1
- provide Example 2
- provide Examples 3-50
- provide Example 51
- provide Examples 52-67

### In Vitro and In Vivo Assays for Identification of Compounds with SARM Activity

- introduce hydroxylapatite-based radioligand displacement assay
- describe binding buffer and wash buffer preparation
- outline cell passaging and preparation of MDA-MB-453 cell lysate
- detail procedure for multiple compound screening
- introduce MMP1 promoter suppression, transient transfection assay (TRAMPS)
- describe transfection and treatment of HepG2 cells
- outline measurement of luciferase activity
- introduce mammalian two-hybrid assay for ligand-induced interaction of N-terminus and C-terminus domains of androgen receptor (agonist
- describe transfection of CV-1 cells
- outline measurement of luciferase activity
- introduce mammalian two-hybrid assay for inhibition of interaction between N-terminus and C-terminus domains of androgen receptor (antagonist
- describe treatment of CV-1 cells with test compounds and R1881
- outline measurement of luciferase activity
- introduce trans-activation modulation of androgen receptor (TAMAR) assay
- describe transfection and treatment of MDA-MB-453 cells
- introduce in vivo prostate assay
- describe in vivo bone formation assay

